OR WAIT null SECS
Becomes a partner in UK consortium focused on enabling new and disruptive manufacturing technologies
CPI has signed an agreement with PwC, making it a partner in the Medicines Manufacturing Innovation Centre collaboration. The partnership will use PwC’s international reach, expertise and experience within the life sciences sector to help benefit patients, push economic growth and help associate the UK as a driving force when it comes to advanced medicines manufacturing innovations.
PwC will join founding partners CPI, the University of Strathclyde, GSK and AstraZeneca to tackle challenges and maximize technology opportunities within the pharma supply chain. According to CPI, this will be accomplished through the flagship “Grand Challenge” projects, which aim to further emergent and disruptive technologies. The program is part-funded by Innovate UK through the Industrial Strategy Challenge Fund and Scottish Enterprise via the Scottish government.
PwC will be increasing opportunities for business development by using its global connectivity and brand authority. In addition, the professional services network will evaluate the marketplace for future technologies. The firm will also develop market analysis and studies to communicate the value of current and future projects, while helping to seek funding from private investors, industry and government.